Tiotropium Bromide + Formoterol Fumarate + CiclesonideThird Party Manufacturing in India

Tiotropium Bromide + Formoterol Fumarate + Ciclesonide works by deploying a triple-action therapeutic mechanism that tackles inflammation, cholinergic bronchoconstriction, and adrenergic muscle relaxation simultaneously. Ciclesonide serves as a prodrug corticosteroid activated locally in the lungs to minimize systemic side effects, while tiotropium provides long-acting anticholinergic blockade and formoterol delivers rapid, sustained beta2-stimulation. Unlike dual therapies, this combination addresses refractory respiratory diseases that do not respond to standard measures. It is highly effective and well-tolerated for advanced clinical stages. The clinical validation of Tiotropium Bromide + Formoterol Fumarate + Ciclesonide third party manufacturing in India highlights its place as a premium tier product. The primary active component is tracked under CAS number 136310-93-5.

Therapeutic Uses

• Severe Chronic Asthma: Indicated for patients whose symptoms are inadequately controlled by dual combination regimens.
• Advanced COPD Therapy: Used to manage severe chronic obstructive pulmonary disease with recurrent exacerbations.

Why Manufacturers Choose Tiotropium Bromide + Formoterol Fumarate + Ciclesonide

Celesta Healthcare leverages over two decades of industry insight to bring advanced triple-drug combinations to market. Our production facilities are WHO-GMP certified, utilizing isolator technologies to maintain the highest standard of active ingredient blending. Selecting a premium Tiotropium Bromide + Formoterol Fumarate + Ciclesonide third party manufacturer in India secures an exclusive edge over competitors.